Essential technologies keep ClinVio secure and remember your choices. With your permission, Google Analytics helps us improve our public website. Optional Analytics is off until you choose.
Cookie Policy · Privacy Policy. You can change your choice at any time using Cookie preferences.
Explore global clinical trial activity by specialty, country, phase, and therapeutic area. Create your ClinVio™ profile to be considered for adjudication, medical review, advisory, and specialist-support opportunities.
Live Trial Activity
Calculated from the trials currently indexed in ClinVio. Hover or focus any metric for its definition and source.
44,433
Total Trials Indexed
44,425
Currently Recruiting
14
Medical Specialties
164
Countries
5,313
Phase II Trials
2,284
Phase III Trials
+7,886
Added (30 days)
Live from ClinicalTrials.gov & EU Register
44,433 trials indexed · showing the latest 500
Showing 1–12 of 500 matching in the latest 500 indexed
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.
Source: Verified clinical trial databases & partner networks· Updated Oct 25, 2026
The main objective of this longitudinal, multi-center study is to explore the clinical characteristics of PD and confirm biomarkers for PD evolution or progression.
Source: Verified clinical trial databases & partner networks· Updated Oct 25, 2026
The goal of this study is refine the usability of a BCI based communication platform. The study will take place in the greater Los Angeles area and will enroll up to 10 participants with late stage ALS. Each subject will receive a Cognixion Axon-R augmented reality brain computer interface and associated communication software. The study duration is 3 months for each participant. The key questions that will be addressed in this study are: 1. How quickly can participants learn and gain confidence with a pure BCI interface. 2. How effective are alternate input modalities including eye tracking for this use case. 3. Identify the extent to which generative AI based personalization impacts the communication quality. Key measures include: ITR - information transfer rate SUS - system usability scale
Source: Verified clinical trial databases & partner networks· Updated Oct 25, 2026
The goal of this clinical trial is to find out whether giving vitamin D to pregnant women who had pre-eclampsia in a previous pregnancy helps prevent the condition from coming back. The main question it aims to answer is: Does vitamin D supplementation reduce the chance of pre-eclampsia recurring in pregnant women with a history of pre-eclampsia? To answer this question, pregnant women attending the antenatal clinic at the Department of Obstetrics and Gynaecology, Nishtar Hospital Multan will be invited to join the study. Participants will be randomly assigned to two equal groups: * Vitamin D group: will take 4,000 IU of oral vitamin D until 36 weeks of gestation. * Placebo group: will receive a pill identical in appearance, taste, and consistency but without vitamin D. While on the study medication, each woman will visit the clinic every two weeks. At each visit, her blood pressure will be measured, and if it is 140/90 mmHg or higher, a urine test will check for protein to identify pre-eclampsia as per hospital protocol. Any diagnosis of pre-eclampsia will lead to standard care, and the outcome will be recorded. At the end, researchers will compare how many women in each group developed recurrent pre-eclampsia. This study will help answer whether vitamin D supplementation can safely reduce the risk of pre-eclampsia returning in women with a prior history - a question important for improving pregnancy outcomes and maternal health.
Source: Verified clinical trial databases & partner networks· Updated Oct 25, 2026
The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
Source: Verified clinical trial databases & partner networks· Updated Oct 25, 2026
Children undergoing general anesthesia for surgery commonly need sedative and anxiolytic premedication but little clinical evidence supports is benefit for children older than 7 years old. The aim of this prospective randomized clinical trial is to assess the impact of pharmacologic premedication on perioperative children experience.
Source: Verified clinical trial databases & partner networks· Updated Oct 25, 2026
The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.
Source: Verified clinical trial databases & partner networks· Updated Oct 24, 2026
This study evaluates the combination of the autophagy inhibitor hydroxychloroquine (HCQ), the MEK inhibitor tunlametinib, and the anti-PD-1 antibody pucotenlimab in patients with locally advanced or metastatic melanoma. The primary objectives are to assess the objective response rate (ORR) and progression-free survival (PFS). Secondary objectives include evaluating adverse events (type, severity, and incidence), duration of response (DOR), disease control rate (DCR), and overall survival (OS), as well as exploring the molecular mechanisms by which autophagy modulation enhances immunogenicity in mutant melanoma. Further exploratory analyses will examine the mechanisms by which autophagy inhibition enhances tumor sensitivity to PD-1 blockade, thereby establishing experimental and theoretical grounds for refining future clinical approaches.
Source: Verified clinical trial databases & partner networks· Updated Oct 24, 2026
This registry trial is designed to track the local control rates and side effects of IORT, which will be implemented for women who are suitable partial breast irradiation (PBI) per the latest American Society of Radiation Oncology (ASTRO) guidelines.
Source: Verified clinical trial databases & partner networks· Updated Oct 24, 2026
Shifting away from a medication-centered approach is a major public health priority, particularly in chronic pain management, where non-pharmacological therapies are recommended despite barriers such as limited evidence and low prescriber awareness. SCENAR (Self-Controlled Energo-Neuro Adaptive Regulation), an electrotherapy device, lacks robust randomized controlled trial data. A prior study showed effects in both active and placebo groups after a single session, supporting further investigation. This study aims to assess whether repeated SCENAR sessions improve disability, mobility, and pain in patients with chronic neck pain.
Source: Verified clinical trial databases & partner networks· Updated Oct 24, 2026
Regular exercise can improve function and quality of life as well as have other positive behavioral and health-related benefits in people Parkinson's disease (PD). Despite the benefits, insufficient exercise is common among PD individuals, often due to common barriers, emphasizing the importance of empowering individuals with adequate knowledge and self-management skills. This project aims to develop "Engage-Qatar PD," an online physical activity self-management program for people with PD in Qatar. Engage-Qatar PD will be grounded in a previously developed coaching intervention used in people with Huntington's disease (Engage HD) and people with PD. The main focus of this project will be the development work to adapt this intervention for online delivery for people with PD and within the Qatari context. This development stage will entail participatory design, in which users will be actively involved as co-designers to ensure fully the required cultural adaptations. Following this development phase, a pilot randomized controlled trial will be conducted to assess the feasibility, acceptability, and potential benefits of the developed intervention. The innovative approach proposed for this project would have wide-reaching impact, advancing the development of new therapeutic options. It will deliver a realistic, culturally adapted therapeutic option for people with PD in Qatar that has the potential to be implemented in a variety of healthcare settings and other countries in the region. Importantly, future work could replicate this program in a larger cohort of individuals with other neurodegenerative diseases and extend this work to other countries in the region.
Source: Verified clinical trial databases & partner networks· Updated Oct 24, 2026
The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.
Source: Verified clinical trial databases & partner networks· Updated Oct 24, 2026
Opportunities by Specialty
Live counts of indexed trials per specialty. Counts are calculated from current trial data, not projected.
How ClinVio Works
ClinVio is more than a trial listing — it is the path from interest to engagement.
Browse indexed trials by specialty, country, phase, and therapeutic area to see where specialist engagement is happening.
Add your specialization, experience, credentials, and availability. Takes only a few minutes.
ClinVio matches your profile to adjudication, review, advisory, and specialist-support opportunities.
Engage on flexible terms with sponsors and CROs, contribute your expertise, and receive compensation.
Why Doctors Join ClinVio
No guaranteed placements or income promises — just relevant opportunities and operational support.
Choose opportunities that fit your schedule — typically 10–40 hours per month, fully remote.
Engage with sponsors and CROs running trials across multiple countries and therapeutic areas.
Hourly, per-case, or monthly compensation models based on the type and duration of engagement.
Your professional information is encrypted in transit and accessed only with role-based permissions.
Receive notifications when new trials match your specialty, phase, and country preferences.
Our team supports onboarding, contracting, and ongoing engagement logistics end-to-end.
Find medical experts for adjudication, review and specialist-support roles.
Trust, Privacy & Security
We describe our actual controls and plans accurately. We do not claim certifications or regulatory approvals that have not been completed.
All data in transit is encrypted using modern TLS standards.
Doctor profile data is only exposed to authorized sponsors after approval.
Profile sharing follows a staged disclosure model with consent tracking.
We follow privacy workflows intended to align with GDPR principles.
Profile views and key data access events are logged for accountability.
SOC 2 readiness planned · HIPAA applicability under review.
Compliance status: ClinVio does not claim HIPAA compliance, SOC 2 certification, FDA approval, or FDA compliance. HIPAA applicability is currently under review and SOC 2 readiness is planned. Regulatory alignments are described as design objectives, not completed certifications.
ClinVio connects medical specialists with sponsors and CROs for clinical trial adjudication, medical review, advisory and specialist-support engagements.
Submit the doctor registration request with your name, email, country, primary specialty and professional background. The ClinVio team reviews your details and emails your login details within 2 working days.
Open doctor registrationNo. Public trial records describe clinical trial activity. A ClinVio engagement depends on a specific requirement, matching, review and agreement with the relevant parties.
The doctor and company portals support engagement contracts, time recording, timesheet review and payment tracking. Compensation and work expectations are set through the applicable engagement and contract.
The Trust Center links to ClinVio policies and describes its security and compliance program status. You can submit a privacy request for review through the Privacy Request page.
Visit the Trust CenterClinVio Blog
Explore clinical research roles, specialist opportunities and practical guides for doctors.
ClinVio InsightsA complete guide to clinical research roles, eligibility requirements and practical steps for doctors who want to get involved in clinical trials.
Read articleSend your registration request in a few minutes. Once approved, usually within 2 working days, you'll start receiving relevant clinical trial opportunity alerts.
Create Your Doctor Profile